Trial registration number
|
CTRI/2021/03/031721 |
Full text link
Last imported at : March 26, 2021, 2:21 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=53532
|
First author
Last imported at : Nov. 26, 2021, 10:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
Dr Bharti Wadhwa
|
Contact
Last imported at : Nov. 26, 2021, 10:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
drbhartitaneja@gmail.com
|
Registration date
Last imported at : March 26, 2021, 2:21 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
2021-03-04
|
Recruitment status
Last imported at : March 26, 2021, 2:21 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
Not recruiting
|
Study design
Last imported at : March 26, 2021, 2:21 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
RCT
|
Allocation
Last imported at : March 26, 2021, 2:21 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
Randomized
|
Design
Last imported at : March 26, 2021, 2:21 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
Parallel
|
Masking
Last imported at : March 26, 2021, 2:21 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
Blind label
|
Center
Last imported at : March 26, 2021, 2:21 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
single-center
|
Study aim
Last imported at : March 26, 2021, 2:21 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
Treatment
|
Inclusion criteria
Last imported at : Nov. 26, 2021, 10:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
Confirmed COVID-19 by RT PCR test <br/ >Hospitalized Non ventilated patients with oxygen by mask or nasal prongs (WHO <br/ >Ordinal Scale 4: Appendix 1) <br/ >SpO2 < 94% on room air but maintaining SpO2 of >94% on VenturiMask / Non <br/ >rebreathing mask <br/ >
|
Exclusion criteria
Last imported at : Nov. 26, 2021, 10:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
Participation in another clinical trial of an investigational medicinal product <br/ > Known hypersensitivity to the IMP <br/ >Significant electrolyte disturbance (Hyperkalemia: K+ >5.0 mmol/L) <br/ >Patient currently receiving potassium sparing diuretics that cannot be reasonably <br/ >withheld <br/ >â?¢ Acute renal insufficiency <br/ >â?¢ In the Investigatorâ??s opinion, patient is unwilling or unable to comply with drug <br/ >administration plan, laboratory tests or other study procedures. <br/ >â?¢ Pregnant or lactating patient <br/ >â?¢ Patients on the following drugs : ACE inhibitors, Amiloride, Hydrocortisone, <br/ >Prednisolone, Methylprednisolone, Triamterene
|
Number of arms
Last imported at : Nov. 26, 2021, 10:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
2
|
Funding
Last imported at : March 26, 2021, 2:21 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
None
|
Inclusion age min
Last imported at : March 26, 2021, 2:21 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
18
|
Inclusion age max
Last imported at : March 26, 2021, 2:21 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
85
|
Countries
Last imported at : Nov. 26, 2021, 10:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
India
|
Type of patients
Last imported at : March 26, 2021, 2:21 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
Moderate/severe disease at enrollment
|
Severity scale
Last imported at : March 26, 2021, 2:21 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
4: Moderate/severe disease at enrollment
|
Total sample size
Last imported at : March 26, 2021, 2:21 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
120
|
primary outcome
Last imported at : Nov. 26, 2021, 10:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
1.The time to recover; defined as the first day; during the 28 days after enrollment; on which a patient met the criteria for category 1;2; 0r 3 WHO ordinal scale. <br/ >2.To determine the effect of the medication on Von Willebrand Factor; Angiotensin II; aldosterone and D-Dimer Levels.Timepoint: Baseline <br/ >Day 1 <br/ >Day 4 <br/ >Day 7
|
Notes
Last imported at : Nov. 26, 2021, 10:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
| Declared number of arm (5.0)
differs from found arms (6.0)
|
Phase
Last imported at : March 26, 2021, 2:21 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
Not reported
|
Arms
Last imported at : Nov. 26, 2021, 10:30 p.m.
Source : International Clinical Trials Registry Platform (ICTRP)
|
[{"arm_notes": "50mg on day 1 followed by 25mg till day 21", "treatment_id": 1228, "treatment_name": "Spironolactone", "treatment_type": "Cardiovascular agents", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "6mg only for ten days", "treatment_id": 400, "treatment_name": "Dexamethasone", "treatment_type": "Corticosteroids", "pharmacological_treatment": "Pharmacological treatment"}]
|